Is Moderna Inc (MRNA) Stock Over or Undervalued?

Moderna Inc (MRNA) receives a strong valuation score of 86 from InvestorsObserver analysis. Our proprietary scoring system considers the overall health of the company by looking at the stock's price, earnings, and growth rate to determine if it represents a good value. MRNA holds a better value than 86% of stocks at its current price. Investors who are focused on long-term growth through buy-and-hold investing will find the Valuation Rank especially relevant when allocating their assets.

MRNA gets a 86 Valuation Rank today. Find out what this means to you and get the rest of the rankings on MRNA!

See Full MRNA Report

Metrics Analysis

MRNA has a trailing twelve month Price to Earnings (PE) ratio of 4.4 which places it below the histroical average of roughly 15. MRNA is currently trading at a good value due to investors paying less than what the stock is worth in relation to its earnings. MRNA's trailing-12-month earnings per share (EPS) of 34.03 does justify its share price in the market. Trailing PE ratios do not factor in the company's projected growth rate, thus, some firms will have high PE ratios caused by high growth recruiting more investors even if the underlying company has produced low earnings so far. MRNA has a 12 month forward PE to Growth (PEG) ratio of 0.84. Markets are overvaluing MRNA in relation to its projected growth as its PEG ratio is currently above the fair market value of 1. 34.0299987's PEG comes from its forward price to earnings ratio being divided by its growth rate. PEG ratios are one of the most used valuation metrics due to its incorporation of more company fundamentals metrics and a focus on the firm's future rather than its past.

Summary

MRNA's valuation metrics are adequate at its current price due to a fairly valued PEG ratio due to strong growth. MRNA's PE and PEG are around the market average resulting in a average valuation score. Click Here to get the full Report on Moderna Inc (MRNA) stock.